Halozyme Therapeutics
HALO
Halozyme Therapeutics (HALO) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| HC Wainwright & Co. | Maintained | Buy | $115.00 from $95.00 | Aug 7, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $95.00 from $75.00 | Aug 7, 2026 |
| Citizens | Maintained | Market Outperform | $93.00 from $92.00 | Aug 7, 2026 |
| TD Cowen | Maintained | Buy | $105.00 from $96.00 | Aug 7, 2026 |
| Leerink Partners | Upgraded | Market Perform → Outperform | $110.00 from $83.00 | Aug 7, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $95.00 | Jul 21, 2026 |
| Morgan Stanley | Maintained | Overweight | $93.00 from $96.00 | May 12, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $95.00 from $90.00 | Apr 29, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $75.00 from $65.00 | Feb 19, 2026 |
| Benchmark | Maintained | Buy | $90.00 from $75.00 | Feb 19, 2026 |
| TD Cowen | Maintained | Buy | $90.00 from $79.00 | Jan 8, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $90.00 | Dec 19, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $90.00 | Nov 28, 2025 |
| Goldman Sachs | Maintained | Neutral | $56.00 from $54.00 | Nov 18, 2025 |
| Citizens | Maintained | Market Outperform | $92.00 from $91.00 | Nov 4, 2025 |
| JP Morgan | Maintained | Neutral | $65.00 from $63.00 | Oct 27, 2025 |
| Morgan Stanley | Maintained | Overweight | $79.00 from $80.00 | Oct 20, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $90.00 | Oct 15, 2025 |
| Leerink Partners | Upgraded | Underperform → Market Perform | $70.00 | Oct 14, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $90.00 from $85.00 | Oct 2, 2025 |
Frequently asked questions
What is the latest analyst rating on HALO?
On Aug 7, 2026, HC Wainwright & Co. maintained Halozyme Therapeutics at Buy with a price target of $115.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.